These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17194493)

  • 21. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB; Adjei AA
    Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
    Kiessling MK; Rogler G
    Swiss Med Wkly; 2015; 145():w14207. PubMed ID: 26691679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperactive Ras in developmental disorders and cancer.
    Schubbert S; Shannon K; Bollag G
    Nat Rev Cancer; 2007 Apr; 7(4):295-308. PubMed ID: 17384584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
    Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
    Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
    Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
    J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
    Brognard J; Dennis PA
    Cell Death Differ; 2002 Sep; 9(9):893-904. PubMed ID: 12181740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.
    Yu Z; Ye S; Hu G; Lv M; Tu Z; Zhou K; Li Q
    Future Med Chem; 2015; 7(3):269-89. PubMed ID: 25826360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
    Miller CR; Oliver KE; Farley JH
    Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
    Roukos DH; Papaloukas C; Tzaphlidou M
    Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
    [No Abstract]   [Full Text] [Related]  

  • 35. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.
    Ruiz-Camps I; Aguilar-Company J
    Infect Dis Clin North Am; 2020 Jun; 34(2):257-270. PubMed ID: 32334988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raf: a strategic target for therapeutic development against cancer.
    Beeram M; Patnaik A; Rowinsky EK
    J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
    Zipser MC; Eichhoff OM; Widmer DS; Schlegel NC; Schoenewolf NL; Stuart D; Liu W; Gardner H; Smith PD; Nuciforo P; Dummer R; Hoek KS
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):326-33. PubMed ID: 21176117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
    El-Nassan HB
    Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Development Status of MEK Inhibitors.
    Cheng Y; Tian H
    Molecules; 2017 Sep; 22(10):. PubMed ID: 28954413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.